Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Reckitt Benckiser is considering the sale of its subsidiary, Mead Johnson Nutritionals, which is based in China. It was said that the British multinational consumer goods company is eyeing at least $2 billion for the deal.
Sources who have knowledge on the matter told Reuters that Reckitt Benckiser already hired the American financial services company, Morgan Stanley, to review its Mead Johnson infant formula unit in Greater China. The insiders were not names since the information shared is confidential.
The plans for the sale of Mead Johnson’s infant formula
Based on the report, Reckitt Benckiser could commence the sale process any time within the second quarter of this year. As soon as the bank receives feedback or recommendation from potential buyers, the sale will begin.
Then again, all the interested parties have been warned that Reckitt Benckiser has not made any definite decision yet, and business valuation could still change because of the negative effects of the COVID-19 pandemic. Moreover, in February, it was said that the company is exploring its other options on how to handle Mead Johnson’s infant formula unit.
In any case, Reckitt Benckiser acquired Mead Johnson in 2017 for $16.6 billion in 2017. The infant formula-maker gave the company billions from the sale of its leading milk brands that include Lactum, Enfapro, and Enfamil.
Why Mead Johnson is being sold
Reckitt Benckiser’s chief executive officer, Laxman Narasimhan, said that there is a big decline in sales in China which makes up 6 percent of the group sales. The reason for the dive is the closure of the Hong Kong border that is taking a long time to re-open due to coronavirus.
Also, the birth rate in one of the most populous countries in the world has gone down as well, so there is less infant to feed with the formula from Mead Johnson. Lastly, Chinese locals have been choosing to buy imported milk due to the 2008 milk contamination controversy scandal. In fact, it was noted that on China’s leading e-commerce platform, JD.Com, the top four best-selling brands of infant formula are all from foreign labels.
